Please wait while the product information is retrieved.
We could not load this product.
Figure: NK cell activation and expansion data
Figure: NK cell natural killing data against K562 cells
Figure: Antibody-mediated NK cell killing data against SK-BR-3 cells
Figure: NK cell in vivo modeling data
At present, various NK cell immunotherapies are being actively developed, with some products in early development or early clinical stages. The predominant approach is direct infusion of autologous or allogeneic NK cells, and a certain proportion involve gene-edited NK cell therapies. How to obtain high-quality NK cells through in vitro culture is a critical challenge in the development of NK cell therapy products. SailyBio has professional NK cell activation and expansion capabilities to address this challenge for clients and shorten development timelines.
SailyBio's NK cell activation and expansion service supports NK cell expansion and NK killing function validation (K562 natural killing, antibody-mediated SK-BR-3 killing, and in vivo modeling). The expanded product can serve as starting material for CAR-NK, supporting CAR-NK cell therapy and NK immunotherapy product development.
Long Press to Scan QR Code
Scan QR Code
